The results demonstrated a significant reduction in the expression of cell proliferation-associated antigen Ki67 and platelet-endothelial cell adhesion molecule CD31 in tumor tissues of the treatment group (Fig. 8F, G). This evidence concerns the gene PECAM1 and neoplasm.